MedTrace Logo

PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

NCT03559114 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1100

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).

Conditions

Interventions

DRUG

Dalteparin

Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.

DRUG

Saline

Saline in prophylactic doses administered daily if screening criteria are satisfied.

Sponsors & Collaborators

  • Sunnybrook Research Institute

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Farhad Pirouzmand, MD, MSc, FRCSC · Sunnybrook Health Sciences Centre

  • Damon Scales, MD, PhD, FRCPC · Sunnybrook Health Sciences Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-19
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03559114 on ClinicalTrials.gov